Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis

Josephine F. Trott, Vicki J. Hwang, Tatsuto Ishimaru, Kenneth J. Chmiel, Julie X. Zhou, Kyuhwan Shim, Benjamin J. Stewart, Moe R. Mahjoub, Kuang-Yu Jen, Dinesh K. Barupal, Xiaogang Li, Robert H Weiss

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. We now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.

Original languageEnglish (US)
Pages (from-to)F1855-F1868
JournalAmerican journal of physiology. Renal physiology
Volume315
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

Autosomal Dominant Polycystic Kidney
Arginine
Glutamine
Renal Cell Carcinoma
Metabolic Diseases
Autosomal Recessive Polycystic Kidney
Citrulline
Metabolomics
Essential Amino Acids
Nephrology
Enzymes
Research
Proline
Neoplasms
Pharmacology
Kidney
Cell Line

Keywords

  • arginine
  • cystogenesis
  • metabolic reprogramming

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. / Trott, Josephine F.; Hwang, Vicki J.; Ishimaru, Tatsuto; Chmiel, Kenneth J.; Zhou, Julie X.; Shim, Kyuhwan; Stewart, Benjamin J.; Mahjoub, Moe R.; Jen, Kuang-Yu; Barupal, Dinesh K.; Li, Xiaogang; Weiss, Robert H.

In: American journal of physiology. Renal physiology, Vol. 315, No. 6, 01.12.2018, p. F1855-F1868.

Research output: Contribution to journalArticle

Trott, JF, Hwang, VJ, Ishimaru, T, Chmiel, KJ, Zhou, JX, Shim, K, Stewart, BJ, Mahjoub, MR, Jen, K-Y, Barupal, DK, Li, X & Weiss, RH 2018, 'Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis', American journal of physiology. Renal physiology, vol. 315, no. 6, pp. F1855-F1868. https://doi.org/10.1152/ajprenal.00025.2018
Trott, Josephine F. ; Hwang, Vicki J. ; Ishimaru, Tatsuto ; Chmiel, Kenneth J. ; Zhou, Julie X. ; Shim, Kyuhwan ; Stewart, Benjamin J. ; Mahjoub, Moe R. ; Jen, Kuang-Yu ; Barupal, Dinesh K. ; Li, Xiaogang ; Weiss, Robert H. / Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. In: American journal of physiology. Renal physiology. 2018 ; Vol. 315, No. 6. pp. F1855-F1868.
@article{5a92f0aee5fd4678b8dca1118f7cf5a7,
title = "Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis",
abstract = "Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. We now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.",
keywords = "arginine, cystogenesis, metabolic reprogramming",
author = "Trott, {Josephine F.} and Hwang, {Vicki J.} and Tatsuto Ishimaru and Chmiel, {Kenneth J.} and Zhou, {Julie X.} and Kyuhwan Shim and Stewart, {Benjamin J.} and Mahjoub, {Moe R.} and Kuang-Yu Jen and Barupal, {Dinesh K.} and Xiaogang Li and Weiss, {Robert H}",
year = "2018",
month = "12",
day = "1",
doi = "10.1152/ajprenal.00025.2018",
language = "English (US)",
volume = "315",
pages = "F1855--F1868",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis

AU - Trott, Josephine F.

AU - Hwang, Vicki J.

AU - Ishimaru, Tatsuto

AU - Chmiel, Kenneth J.

AU - Zhou, Julie X.

AU - Shim, Kyuhwan

AU - Stewart, Benjamin J.

AU - Mahjoub, Moe R.

AU - Jen, Kuang-Yu

AU - Barupal, Dinesh K.

AU - Li, Xiaogang

AU - Weiss, Robert H

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. We now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.

AB - Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. We now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.

KW - arginine

KW - cystogenesis

KW - metabolic reprogramming

UR - http://www.scopus.com/inward/record.url?scp=85055263604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055263604&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00025.2018

DO - 10.1152/ajprenal.00025.2018

M3 - Article

C2 - 30280600

AN - SCOPUS:85055263604

VL - 315

SP - F1855-F1868

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 6

ER -